Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Abbott's White To Step Down as Chief Executive -- WSJ

share with twitter share with LinkedIn share with facebook
share via e-mail
11/14/2019 | 02:48am EST

By Peter Loftus

Abbott Laboratories said Chief Executive Miles D. White, who oversaw the transformation of the health-care-products maker with a series of acquisitions and spinoffs in more than 20 years at the helm, will step down as CEO in March 2020.

The Abbott Park, Ill., company, which makes heart devices, Similac baby formula and diagnostic tests, named Abbott's president and operating chief, Robert B. Ford, to succeed Mr. White, who will remain executive chairman.

Mr. Ford has led various Abbott businesses during his 23 years with the company.

Mr. White has led Abbott since 1999, one of the longest CEO tenures among major U.S. companies.

"It's a good time to transition," Mr. White said in an interview, because he is 64 years of age, and his successor is ready. "I think the company's in the best shape it's ever been in."

Abbott's annual sales grew to $30.6 billion from about $12.5 billion under Mr. White. One of his most consequential deals was Abbott's 2001 acquisition of Knoll Pharmaceuticals from BASF for $7.2 billion, which landed Abbott the arthritis drug Humira.

Humira, which also treats a range of other diseases, went on to become the highest-selling prescription drug in the world.

Abbott in 2013 spun off its core pharmaceutical business, including Humira, as a new company named AbbVie Inc., after Mr. White concluded that business was headed in a different direction than the rest of Abbott's divisions.

More recently, Abbott in 2017 acquired St. Jude Medical for $23.6 billion, expanding Abbott's medical-device business. Mr. White said he has "changed the company a couple of times along the way" to adapt to changes in technology and the practice of medicine.

Evercore ISI analyst Vijay Kumar said in a research note that Mr. White was a "larger than life figure" at Abbott, who delivered strong returns for shareholders. Mr. White, a former McKinsey & Co. consultant, joined Abbott in 1984.

Abbott's shares were relatively flat during afternoon trading on the New York Stock Exchange.

Mr. Ford, 46, was named president of Abbott in 2018, a move that telegraphed the succession plan. He previously led Abbott's medical-device business, oversaw the launch of the fast-selling FreeStyle Libre glucose monitor for diabetes and led the integration of the St. Jude acquisition.

Mr. Ford said in an interview he plans to focus on continued growth of FreeStyle Libre, diagnostics and Abbott's emerging-markets business. Mindful of Silicon Valley's growing interest in health care, Mr. Ford also said he plans to make sure Abbott adapts to consumers' use of phones and other connected devices to monitor their health.

Abbott's board has named Mr. Ford a director. He has a bachelor's degree from Boston College and a master's degree in business administration from the University of California, Berkeley, Haas School of Business.

Write to Peter Loftus at peter.loftus@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 0.85% 81.85 Delayed Quote.-2.57%
ABBVIE INC. 0.64% 89.77 Delayed Quote.0.72%
BASF SE -0.30% 57.42 Delayed Quote.-14.49%
EVERCORE INC. -2.08% 72.39 Delayed Quote.-1.18%
KNOLL, INC. -2.44% 19.17 Delayed Quote.-22.25%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBOTT LABORATORIES
02/24Board of directors meeting of Abbott Laboratories Limited
AQ
02/24ABBOTT LABORATORIES : Declares 385th consecutive quarterly dividend
AQ
02/21ABBOTT LABORATORIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
02/21ABBOTT : Declares 385th Consecutive Quarterly Dividend
PR
02/18ABBOTT : Introduces Next-Generation Heart Rhythm Management Devices in Europe, F..
PR
02/11ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
02/05WALL STREET STOCK EXCHANGE : Tiffany is part of LVMH, Tesla gives some bad news,..
02/04ABBOTT LABORATORIES : Gets FDA Breakthrough Designation for Fully Implantable He..
DJ
02/04ABBOTT : 's In-Development Fully Implantable Heart Pump System Earns FDA's Break..
PR
02/03ABBOTT : Announces First-of-Its-Kind Trial to Assess New Therapy Option for Peop..
PR
More news
Financials (USD)
Sales 2020 34 120 M
EBIT 2020 7 754 M
Net income 2020 4 460 M
Debt 2020 10 170 M
Yield 2020 1,72%
P/E ratio 2020 32,1x
P/E ratio 2021 26,2x
EV / Sales2020 4,49x
EV / Sales2021 4,07x
Capitalization 143 B
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 99,06  $
Last Close Price 81,13  $
Spread / Highest target 35,6%
Spread / Average Target 22,1%
Spread / Lowest Target -3,86%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Robert B. Ford President, Chief Operating Officer & Director
Brian Bernard Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES-2.57%143 067
MASIMO CORPORATION9.63%9 083
NOVOCURE LIMITED-5.03%7 920
ASAHI INTECC CO., LTD.1.97%6 243
JIANGSU YUYUE MDCL EQPMNT & SPPLY CO LTD--.--%4 724
GETINGE-5.14%4 625